Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Table 1

Patients’ characteristics.

Characteristics	Population (𝑛=156)
Median age, years (range)	52 (17–69)
Patient sex, 𝑛 (%)
Female	64 (41%)
Sex-mismatch, 𝑛 (%)
Female to male	41 (26.3%)
Diagnosis, 𝑛 (%)
AML/MDS	28 (18%)/17 (11%)
ALL	5 (3%)
NHL/CLL	30 (20%)/11 (7%)
HD	23 (15%)
MM	33 (21%)
CML/other CMPN	7 (5%)/2 (1%)
ECOG, 𝑛 (%)
0	135 (86.5%)
1	10 (6.4%)
2	11 (7.1%)
Reason for RIC, 𝑛 (%)
Advanced age	77 (49.4%)
Multiple prior lines of treatment and/or prior transplantation	24 (15.4%)
Comorbidities and/or ECOG >1	10 (6.4%)
More than one reason	45 (28.8%)
Disease status, 𝑛 (%)
Early phase	72 (46%)
Advanced phase	84 (54%)
Renal impairment before SCT, 𝑛 (%)
None	129 (83%)
GFR 50–60 mL/min	16 (10%)
GFR 40–50 mL/min	9 (6%)
GFR < 40mL/min	2 (1.3%)
CMV serostatus; (donor and receptor negative), 𝑛 (%)	10 (6.4 %)
Conditioning regimen, 𝑛 (%)
Fludarabine-melphalan	103 (65%)
Fludarabine-busulfan	53 (35%)
CD34^+ × 10E6/kg infused, median (range)	6.7 (1.6–15.6)
GVHD prophylaxis, 𝑛 (%)
CsA-MTX	121 (77.6%)
CsA-MMF	35 (22.4%)
Follow-up for survivors in months: median (range)	67 (5–121)

Notes: AML: acute myeloid leukemia; MDS: myelodisplastic syndrome; ALL: acute lymphatic leukemia; NHL: non-Hodgkin lymphoma; CLL: chronic lymphoid leukemia; HD: Hodgkin disease; MM: multiple myeloma; CML: chronic myeloid leukemia; CMPN: chronic myeloproliferative neoplasms; GFR: glomerular filtration rate.